Dixon Hubard Feinour & Brown Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$5.82M |
| 2 |
Cintas
CTAS
|
+$5.14M |
| 3 |
Oshkosh
OSK
|
+$4.9M |
| 4 |
HealthEquity
HQY
|
+$4.67M |
| 5 |
Teradyne
TER
|
+$4.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PetMed Express
PETS
|
+$10.8M |
| 2 |
Lam Research
LRCX
|
+$6.62M |
| 3 |
Danaher
DHR
|
+$5.11M |
| 4 |
Eagle Materials
EXP
|
+$5.1M |
| 5 |
NBL
Noble Energy, Inc.
NBL
|
+$4.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.88% |
| 2 | Industrials | 14.93% |
| 3 | Technology | 14.51% |
| 4 | Financials | 13.13% |
| 5 | Communication Services | 8.51% |
Similar funds
Dixon Hubard Feinour & Brown's Q3 2017 Portfolio in Review
As of Q3 2017, Dixon Hubard Feinour & Brown held 199 positions worth $348M, up 0.64% from $346M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Dixon Hubard Feinour & Brown withdrew a net $11.3M in Q3 2017, closing 12 positions and reducing 87 holdings. Its most notable exit was PetMed Express, an estimated $10.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 20% a quarter earlier, followed by Industrials and Technology.
Against the trend, Dixon Hubard Feinour & Brown opened a new position in Cintas worth $5.57M.
- Dixon Hubard Feinour & Brown's largest Q3 2017 buy was Cintas: 154,360 shares worth $5.57M.
- Dixon Hubard Feinour & Brown added most to Celgene Corp in Q3 2017, an estimated $5.82M increase.
- Dixon Hubard Feinour & Brown's biggest Q3 2017 reduction was Meta Platforms (Facebook), cutting an estimated $337K.
- Dixon Hubard Feinour & Brown fully exited PetMed Express in Q3 2017, selling an estimated $10.8M.
- Dixon Hubard Feinour & Brown's ten largest holdings make up 25% of its $348M portfolio in Q3 2017.
- Dixon Hubard Feinour & Brown opened 16 new positions and closed 12 in Q3 2017.
- Dixon Hubard Feinour & Brown's portfolio value rose 0.64% quarter-over-quarter to $348M.
Based on Dixon Hubard Feinour & Brown's 13F filing for Q3 2017, filed 8 Nov 2017.